MA-IPANEMA-TECHNOLOGIES
23.2.2015 14:14:18 CET | Business Wire | Pressemeddelelse
Ipanema Technologies – the industry leader in network solutions enabling enterprises to guarantee their application performance, today announced it appointed Ben Heisler as Senior Vice-President for sales in the Americas. Based in New York, Mr. Heisler will lead growth initiatives and be responsible for overseeing sales and partnerships in the region. He will report directly to Ipanema Technologies’ CEO, Jim Darragh.
Mr. Heisler joins Ipanema after two years as Area Vice-President at Zeus Technology, which was acquired by Riverbed. He also held a senior position at Coraid, which provides storage solutions for cloud service providers and enterprises. Prior to this, his experience includes roles at Opalis Software, VERITAS, Oracle and ADP.
His appointment follows recent successes for Ipanema in the U.S., including partnerships with leading service providers such as AT&T and Link America. These service providers use Ipanema to offer their enterprise customers high value-added managed services that guarantees their application SLAs (cloud or on-premise) across global WANs.
“Real market leadership is measured by proven value delivered to customers and an agile business strategy and execution”, said Jim Darragh, CEO at Ipanema Technologies . “Ipanema is taking advantage of the current market volatility by further investing in the Americas market. Ben Heisler has an extraordinary wealth of knowledge in cutting edge networking technology, combined with a passion for excellence in global business leadership. I believe that he will take Ipanema to the next level and bring opportunities and growth in North America” , he added.
“I’m very proud to be part of this adventure and build on the already solid foundations here in the N. America, Ipanema is the only company I looked at that could provide an integrated suite for actionable intelligence of your applications on the network. The platform is best of breed in that it is open, fully featured, integrated and purpose built to solve this problem head on. This unique approach from an application down vs. merely a stale packet inspection approach will make us quickly successful in North America.” states Mr. Heisler .
Today’s ever-changing technology landscape, from the rapidly increasing adoption of cloud computing, SaaS based applications and Unified Communications to the mounting complexity within IT operations, is driving the need for more intelligent solutions.
IT departments are expressing the need to support digital transformation and align application performance with business priorities. A strategic, global and business driven approach to application performance management is becoming critical for IT executives to support companies’ business goals.
The Ipanema System enables large enterprises to adapt to what is happening in the network, and guarantees constant control of critical applications. It is the only fully integrated objectives based system that scales to the levels required by large enterprises.
-Ends-
About Ipanema Technologies www.ipanematech.com
With Ipanema, (Re)discover Simplicity to guarantee your application performance.
Contact:
Ipanema Technologies
Press Contact:
Béatrice
Piquer, Tel. +33 (0)1 55 52 15 37
Vice-President Marketing
piquer@ipanematech.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum